ProPhase Labs Secures Financing to Propel Business Growth
Strengthening liquidity for future endeavors
ProPhase Labs, Inc. (NASDAQ: PRPH) has successfully closed a significant financing deal with two investors, totaling $3 million through a private placement of senior secured convertible notes. This strategic move is poised to act as a financial bridge, facilitating proactive engagement in various upcoming liquidity events and crypto-related ventures.
The financing arrangement, which includes the notes with a 20% original issue discount, allows ProPhase to secure its assets as collateral. Importantly, these notes will not be convertible within the first four months following issuance, and they can be prepaid at any time without incurring penalties. Additionally, accompanying warrants enable investors to purchase shares of common stock at an exercise price of $0.50 per share. This financing aligns with the terms outlined in a Securities Purchase Agreement, ensuring the company authorizes additional common stock shares while moving towards an efficient registration statement.
ProPhase Labs plans to deploy the proceeds from this financing primarily for working capital, general corporate needs, and addressing certain existing debts. This funding will provide crucial support as the company looks to capitalize on potential liquidity events that may arise in the near future.
Leadership Insights on the Financing Impact
Ted Karkus, the Chief Executive Officer of ProPhase Labs, enthusiastically remarked, "This financing provides ProPhase with critical bridge capital as we actively pursue various near-term liquidity prospects. Notably, there is the possibility of collecting up to $50 million in Covid accounts receivable alongside exploring the sale of Nebula Genomics. Furthermore, these funds will bolster our recent initiatives to examine a potential reverse merger crypto treasury strategy, leveraging Nebula Genomics’ extensive expertise in blockchain technology along with other innovative cryptocurrency strategies."
Details Surrounding the Notes and Warrants
The convertible notes and accompanying warrants were offered in a private placement, adhering to Regulation D as per the Securities Act of 1933. It is significant to highlight that these securities have not been registered under the Securities Act or state laws and cannot be offered or sold in the United States unless there is proper registration or an applicable exemption.
About ProPhase Labs Inc.
As a groundbreaking biotech and genomics company, ProPhase Labs, Inc. (NASDAQ: PRPH) is focused on enhancing health and wellness through innovative solutions and actionable insights. Their commitment extends to revolutionizing healthcare with advanced Whole Genome Sequencing technology and cutting-edge diagnostic development, including a potentially life-saving early detection test for esophageal cancer. The company also thrives on its world-class direct-to-consumer marketing of OTC dietary supplements.
ProPhase Labs strives for operational excellence and aligns its diverse projects synergistically to create significant long-term value. The impressive growth of its subsidiaries reflects the company's dedication to advancing health solutions that empower individuals to lead healthier lives.
Contact Information for Investors
For those interested in media relations or institutional investment inquiries, the point of contact is ProPhase Labs, Inc. For email correspondence, please reach out to investorrelations@prophaselabs.com.
For retail investor queries, Renmark Financial Communications can be reached. John Boidman is available at jboidman@renmarkfinancial.com, and can also be contacted via telephone at (416) 644-2020 or (212) 812-7680.
Frequently Asked Questions
What is the purpose of the $3 million financing?
The financing aims to provide ProPhase Labs with essential liquidity for working capital, debt repayment, and future strategic initiatives, particularly in health and blockchain sectors.
How does this financing affect ProPhase Labs' stock?
The issuance of convertible notes and warrants has the potential to impact the stock based on future conversion and exercise of these securities by investors.
What is included in the financing package?
The deal includes $3 million in senior secured convertible notes that were issued with a 20% discount, as well as warrants for purchasing shares of common stock.
What initiatives will the financing support?
The funding will support various initiatives, including the collection of Covid accounts receivable and exploration of a crypt treasury strategy leveraging blockchain technology.
How can investors reach ProPhase Labs for inquiries?
Investors can contact ProPhase Labs through their investor relations email at investorrelations@prophaselabs.com or via phone contacts provided in their public communications.
